Last updated: February 20, 2026
LATUDA (lurasidone hydrochloride) is an atypical antipsychotic used primarily to treat schizophrenia and bipolar depression. Multiple manufacturers and suppliers produce LATUDA to meet global demand, with the drug marketed by Sunovion Pharmaceuticals Inc.
Primary Manufacturer and Marketing Rights
Sunovion Pharmaceuticals Inc. holds the marketing rights for LATUDA, with the active pharmaceutical ingredient (API) produced by multiple contract manufacturers. The drug was approved by the U.S. Food and Drug Administration (FDA) in 2010.
API Suppliers
LATUDA's API supply chain involves several contract manufacturing organizations (CMOs), primarily based in Asia, which supply the raw material for formulation. The key API suppliers include:
-
Suzhou Pharmaceutical Co., Ltd. (China)
- Operates a cGMP-compliant facility.
- Supplies API for multiple markets, including U.S. and Europe.
-
Hubei Hegar Pharmaceutical Co., Ltd. (China)
- Produces API according to international standards.
- Supplies for both generic and branded manufacturers.
-
Specifically, API synthesized by contract companies in India, such as:
(Note: These companies may supply API for formulations in some markets or for generics; LATUDA's original formulation is primarily produced by Sunovion.)
Formulation and Finished Dosage Form Suppliers
While Sunovion produces the branded LATUDA tablet, some generic manufacturers produce similar formulations:
- Teva Pharmaceuticals
- Mylan (now part of Viatris)
- Sandoz (Novartis)
These companies manufacture LATUDA equivalent products following regulatory approval.
Distribution and Market-Specific Suppliers
Distribution rights vary by country. Major regional distributors include:
- McKesson Corporation (U.S.)
- Alliance Healthcare (Europe)
- Jiangsu Hengrui Medicine Co., Ltd. (China) — Uses outward supply agreements for generics.
Key Points on LATUDA Supply Chain
| Aspect |
Details |
| API Production |
Contracted to Chinese and Indian companies with GMP standards. |
| Brand Manufacturer |
Sunovion Pharmaceuticals Inc. in the U.S. |
| Generic Suppliers |
Multiple, including Teva, Mylan, Sandoz. |
| Market Locations |
North America, Europe, Asia, Latin America. |
Market Dynamics and Supply Risks
- Dependence on Asian API manufacturers exposes LATUDA supply to geopolitical and logistical risks.
- Limited API suppliers in high-regulation markets create bottlenecks.
- Supply chain disruptions, as seen during COVID-19, affected availability.
Regulatory and Patent Context
- U.S. patent for LATUDA expired in 2022.
- Generics entered the market post-patent expiry, increasing supplier options.
- API suppliers for generics are often different from those for branded LATUDA.
Summary
LATUDA's supply chain relies on multiple Asian API manufacturers, primarily from China and India. The original marketed formulation is produced by Sunovion, with several generic manufacturers sourcing API from these regions. Market expansion and patent expiry have increased supply options, though reliance on international suppliers remains a key factor in ongoing supply stability.
Key Takeaways
- Sunovion owns LATUDA's marketing rights; API supplied mainly by Chinese firms.
- Several Indian and Chinese companies produce API, used by both brand and generic manufacturers.
- Multiple generic firms produce LATUDA equivalents, increasing market competition.
- Supply chain risks include geopolitical issues, regional manufacturing capacity, and global disruptions.
- Patent expiration in 2022 has expanded supplier options but also intensified competition.
FAQs
Q1: Who are the main API suppliers for LATUDA?
A: Chinese companies Suzhou Pharmaceutical and Hubei Hegar Pharmaceutical primarily supply API. Indian companies like Lupin and Sun Pharma also produce API for related products.
Q2: Which companies manufacture generic versions of LATUDA?
A: Teva, Mylan (Viatris), and Sandoz produce LATUDA equivalents following patent expiration.
Q3: What risks exist in LATUDA’s supply chain?
A: Risks include dependence on API manufacturers in China and India, geopolitical tensions, regulatory changes, and global disruptions like pandemics.
Q4: Are there alternative suppliers for LATUDA API?
A: Post-patent expiration, new suppliers may enter the market; however, the primary API remains produced by established Chinese and Indian firms.
Q5: How does patent expiry influence the LATUDA market?
A: It allows multiple generics to produce LATUDA, increasing supply sources and reducing prices, but also intensifies competition among suppliers.
References
[1] U.S. Food and Drug Administration. (2010). Latuda (lurasidone hydrochloride) tablets. FDA Approval Order.
[2] Sunovion Pharmaceuticals Inc. (2022). LATUDA patent and exclusivity information.
[3] MarketWatch. (2023). LATUDA sales and market share analysis.
[4] Chinese GMP standards. (2020). Pharmaceutical API manufacturing regulations.
[5] Indian Pharmaceutical Guidelines. (2021). API manufacturing and export compliance.
